Trial · NCT01714323

Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers

NCT01714323, Not applicable, Completed, Massachusetts General Hospital; results first posted 2018-06-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers. Trials, record NCT01714323. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01714323

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers
NCT number: NCT01714323
Status: Completed
Phases: Not applicable
Enrollment: 1,359 participants, actual
Lead sponsor: Massachusetts General Hospital
Conditions: Cigarette Smoking, Tobacco Smoking, Tobacco Use Disorder
Interventions: Sustained Care, Standard Care
First posted: 2012-10-25
Last updated: 2018-06-08
Results first posted: 2018-06-08

Source ClinicalTrials.gov

Registered outcomes7

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Tobacco Abstinence - 6 Month Follow-up	6 months	Cotinine-validated 7-day point prevalence tobacco abstinence at 6 month follow-up
Secondary	Continuous Tobacco Abstinence	1 month, 3 months, 6 months	Continuous tobacco abstinence after hospital discharge assessed by self-report at 1, 3, and 6 months.
Secondary	Point Prevalence Tobacco Abstinence	1 month, 3 months, 6 months	7-day point prevalence tobacco abstinence after hospital discharge, assessed by self-report
Secondary	Duration of Tobacco Abstinence After Hospital Discharge	1 month, 3 months, 6 months	Self-reported number of days in which a participant was abstinent from tobacco after hospital discharge, by self-report, obtained from surveys done at 1 month, 3 months, and 6 months. Patient can only relapse once but it can occur at any point up to 6 months after discharge. Therefore, the data point can come from either the 1 or 3 or 6 month follow-up depending on when relapse occurred.
Secondary	Use of Smoking Cessation Treatment After Hospital Discharge	1 month, 3 months, 6 months	Use of either FDA-approved pharmacotherapy for tobacco dependence (nicotine replacement therapy, bupropion, or varenicline), or psychosocial support (including telephone counseling, in person counseling, web-based counseling, physician counseling).
Other	All-cause Hospitalizations	12 months	Self-reported admission to a hospital in the 12 months after the index hospitalization.
Other	All-cause Mortality	6 months	Death from any cause in the 6 months after hospital discharge

Source ClinicalTrials.gov

Outcomes7

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Tobacco Abstinence - 6 Month Follow-up	6 months	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Continuous Tobacco Abstinence	1 month, 3 months, 6 months	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Point Prevalence Tobacco Abstinence	1 month, 3 months, 6 months	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Duration of Tobacco Abstinence After Hospital Discharge	1 month, 3 months, 6 months	days	MEDIAN
SECONDARY	Use of Smoking Cessation Treatment After Hospital Discharge	1 month, 3 months, 6 months	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	All-cause Hospitalizations	12 months	hospital admissions	NUMBER
OTHER_PRE_SPECIFIED	All-cause Mortality	6 months	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group26

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Tobacco Abstinence - 6 Month Follow-up	Standard Care		105	Participants
Tobacco Abstinence - 6 Month Follow-up	Sustained Care		113	Participants
Continuous Tobacco Abstinence	Standard Care	1 month follow-up	179	Participants
Continuous Tobacco Abstinence	Sustained Care	1 month follow-up	211	Participants
Continuous Tobacco Abstinence	Standard Care	3 month follow-up	122	Participants
Continuous Tobacco Abstinence	Sustained Care	3 month follow-up	147	Participants
Continuous Tobacco Abstinence	Standard Care	6 month follow-up	101	Participants
Continuous Tobacco Abstinence	Sustained Care	6 month follow-up	121	Participants
Point Prevalence Tobacco Abstinence	Standard Care	1 month follow-up	217	Participants
Point Prevalence Tobacco Abstinence	Sustained Care	1 month follow-up	295	Participants

1 to 10 of 26Source ClinicalTrials.gov

See all 26 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Standard Care	677
Overall Study	STARTED	Sustained Care	680
Overall Study	COMPLETED	Standard Care	513
Overall Study	COMPLETED	Sustained Care	508
Overall Study	NOT COMPLETED	Standard Care	164
Overall Study	NOT COMPLETED	Sustained Care	172

Source ClinicalTrials.gov

Adverse events46

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
serious	Hospital Readmission	Gastrointestinal disorders	Standard Care	66	677
serious	Hospital Readmission	Gastrointestinal disorders	Sustained Care	70	680
serious	Hospital Readmission	Blood and lymphatic system disorders	Standard Care	19	677
serious	Hospital Readmission	Blood and lymphatic system disorders	Sustained Care	4	680
serious	Hospital Readmission	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Standard Care	6	677
serious	Hospital Readmission	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Sustained Care	8	680
serious	Hospital Readmission	Cardiac disorders	Standard Care	50	677
serious	Hospital Readmission	Cardiac disorders	Sustained Care	48	680
serious	Hospital Readmission	Skin and subcutaneous tissue disorders	Standard Care	21	677
serious	Hospital Readmission	Skin and subcutaneous tissue disorders	Sustained Care	15	680

1 to 10 of 46Source ClinicalTrials.gov

See all 46 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Standard Care
Total, all-cause mortality	Sustained Care
Total, other adverse events	Standard Care	0	677
Total, other adverse events	Sustained Care	0	680
Total, serious adverse events	Standard Care	224	677
Total, serious adverse events	Sustained Care	216	680

Source ClinicalTrials.gov

Papers6

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
25879193	DERIVED	PubMed
27647060	DERIVED	PubMed
28616847	DERIVED	PubMed
29582077	DERIVED	PubMed
30156578	DERIVED	PubMed
31687769	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01HL111821	Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers	RIGOTTI, NANCY A; TINDLE, HILARY A.	MASSACHUSETTS GENERAL HOSPITAL	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE	2012 to 2021

Source NIH RePORTER

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Sustained Care vs Standard Care: Tobacco Abstinence - 6 Month Follow-up	Trial comparisons
Sustained Care vs Standard Care: All-cause Mortality	Trial comparisons
Sustained Care vs Standard Care: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01714323

GET https://conductscience.org/api/trials/v1/NCT01714323/results?page=2

API reference For AI assistants